A Study to Test Whether BI 907828 Helps People With Cancer in the Biliary Tract or Pancreas
Status:
Not yet recruiting
Trial end date:
2026-11-25
Target enrollment:
Participant gender:
Summary
This study is open to adults with advanced cancer in the biliary tract or pancreas. This is a
study for people for whom previous treatment was not successful or no treatment exists.
The purpose of this study is to find out whether a medicine called BI 907828 helps people
with cancer in the biliary tract or pancreas. BI 907828 is a so-called MDM2 inhibitor that is
being developed to treat cancer. All participants take BI 907828 as a tablet once every 3
weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and
can tolerate it. They visit the study site regularly.
At the study site, doctors regularly check the size of the tumour and whether it has spread
to other parts of the body. The doctors also regularly check participants' health and take
note of any unwanted effects.